Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

oruka therapeutics inc - ORKA

ORKA

Close Chg Chg %
57.20 5.65 9.88%

Open Market

62.85

+5.65 (9.88%)

Volume: 790.20K

Last Updated:

Jun 4, 2026, 12:52 PM EDT

Trade Now

Company Overview: oruka therapeutics inc - ORKA

ORKA Key Data

Open

$57.46

 Day Range

57.46 - 63.29

52 Week Range

10.77 - 91.00

 Market Cap

$3.45B

Shares Outstanding

60.31M

 Public Float

50.75M

Beta

-0.30

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$2.39

Yield

0.00%

 Dividend

$1.61

EX-DIVIDEND DATE

Aug 29, 2024

 SHORT INTEREST

N/A

AVERAGE VOLUME

1.38M

  

ORKA Performance

1 Week
 
 -2.27%
 
1 Month
 
 -11.44%
 
3 Months
 
 73.49%
 
1 Year
 
 354.69%
 
5 Years
 
 33.52%
 

ORKA Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 14
Full Ratings ➔

About oruka therapeutics inc - ORKA

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

ORKA At a Glance

Oruka Therapeutics, Inc.
855 Oak Grove Avenue
Menlo Park, California 94025
Phone 1-650-606-7910 Revenue 0.00
Industry Pharmaceuticals: Major Net Income -105,433,000.00
Sector Health Technology Employees 68
Fiscal Year-end 12 / 2026
View SEC Filings

ORKA Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 3.149
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -8.612
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.002

ORKA Efficiency

Revenue/Employee N/A
Income Per Employee -1,550,485.294
Receivables Turnover N/A
Total Asset Turnover N/A

ORKA Liquidity

Current Ratio 22.366
Quick Ratio 22.366
Cash Ratio 21.923

ORKA Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -23.836
Return on Equity -24.687
Return on Total Capital -22.25
Return on Invested Capital -24.628

ORKA Capital Structure

Total Debt to Total Equity 0.409
Total Debt to Total Capital 0.408
Total Debt to Total Assets 0.395
Long-Term Debt to Equity 0.28
Long-Term Debt to Total Capital 0.277
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Oruka Therapeutics Inc - ORKA

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
114.00K 111.00K 27.00K 83.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
114.00K 111.00K 27.00K 83.00K
Depreciation
114.00K 111.00K 27.00K 83.00K
Amortization of Intangibles
- - - -
-
COGS Growth
+25.27% -2.63% -75.68% +207.41%
Gross Income
(114.00K) (111.00K) (27.00K) (83.00K)
Gross Income Growth
-25.27% +2.63% +75.68% -207.41%
Gross Profit Margin
- - - -
-
2022 2023 2024 2025 5-year trend
SG&A Expense
9.73M 7.18M 88.10M 121.97M
Research & Development
4.46M 1.01M 75.06M 100.64M
Other SG&A
5.26M 6.17M 13.04M 21.33M
SGA Growth
-49.45% -26.13% +1,126.11% +38.45%
Other Operating Expense
- - - -
-
Unusual Expense
- - - 755.00K
-
EBIT after Unusual Expense
(10.60M) (7.30M) (88.12M) (122.05M)
Non Operating Income/Expense
670.00K 1.96M 5.87M 16.62M
Non-Operating Interest Income
675.00K 1.96M 5.86M 16.63M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - 1.47M
-
Interest Expense Growth
- - - -100.00%
-
Gross Interest Expense
- - - 1.47M
-
Interest Capitalized
- - - -
-
Pretax Income
(9.93M) (5.34M) (83.72M) (105.43M)
Pretax Income Growth
+48.63% +46.21% -1,468.16% -25.93%
Pretax Margin
- - - -
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(9.93M) (5.34M) (83.72M) (105.43M)
Minority Interest Expense
- - - -
-
Net Income
(9.93M) (5.34M) (83.72M) (105.43M)
Net Income Growth
+48.63% +46.21% -1,468.16% -25.93%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(9.93M) (5.34M) (83.72M) (105.43M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(9.93M) (5.34M) (83.72M) (105.43M)
EPS (Basic)
-8.2658 -4.4443 -4.9867 -2.3114
EPS (Basic) Growth
+50.43% +46.23% -12.20% +53.65%
Basic Shares Outstanding
1.20M 1.20M 16.79M 45.61M
EPS (Diluted)
-8.2658 -4.4443 -4.9867 -2.3114
EPS (Diluted) Growth
+50.43% +46.23% -12.20% +53.65%
Diluted Shares Outstanding
1.20M 1.20M 16.79M 45.61M
EBITDA
(9.73M) (7.18M) (88.10M) (121.97M)
EBITDA Growth
+49.45% +26.13% -1,126.11% -38.45%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 140.462
Number of Ratings 14 Current Quarters Estimate -0.513
FY Report Date 06 / 2026 Current Year's Estimate -2.111
Last Quarter’s Earnings -0.48 Median PE on CY Estimate N/A
Year Ago Earnings -1.85 Next Fiscal Year Estimate -2.492
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 12 12 12 12
Mean Estimate -0.51 -0.52 -2.11 -2.49
High Estimates -0.42 -0.38 -1.69 -1.37
Low Estimate -0.67 -0.73 -2.79 -4.12
Coefficient of Variance -14.60 -21.16 -17.37 -28.47

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 13 13 12
OVERWEIGHT 1 1 1
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Oruka Therapeutics Inc - ORKA

Date Name Shares Transaction Value
Apr 16, 2026 Joana Goncalves Chief Medical Officer 36,877 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $6.84 per share 252,238.68
Apr 16, 2026 Joana Goncalves Chief Medical Officer 40,377 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $7.8 per share 314,940.60
Apr 16, 2026 Joana Goncalves Chief Medical Officer 36,150 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $65.73 per share 2,376,139.50
Apr 16, 2026 Joana Goncalves Chief Medical Officer 33,877 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $66.56 per share 2,254,853.12
Apr 16, 2026 Joana Goncalves Chief Medical Officer 33,377 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $67.38 per share 2,248,942.26
Apr 16, 2026 Joana Goncalves Chief Medical Officer 211,063 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 16, 2026 Joana Goncalves Chief Medical Officer 182,492 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 18, 2026 Paul T. Quinlan General Counsel 31,767 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $41.3 per share 1,311,977.10
Mar 18, 2026 Lawrence O. Klein Chief Executive Officer; Director 927,309 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $41.3 per share 38,297,861.70
Mar 18, 2026 Joana Goncalves Chief Medical Officer 185,992 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 18, 2026 Arjun Agarwal Senior Vice President, Finance 18,863 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $41.3 per share 779,041.90
Mar 18, 2026 Laura Sandler Chief Operating Officer 236,984 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $41.3 per share 9,787,439.20
Dec 12, 2025 Christopher Martin Director 35,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Oruka Therapeutics Inc in the News